Core Viewpoint - The company has adjusted the upper limit for the repurchase price of its shares to enhance market value and ensure the smooth implementation of the buyback plan [4][7]. Group 1: Buyback Plan Overview - On January 24, 2025, the company approved a plan to repurchase shares using its own funds and a special loan, with a total repurchase amount between RMB 15 million and RMB 30 million, and an initial price limit of RMB 25.00 per share [2]. - The price limit was adjusted to RMB 24.80 per share starting from July 10, 2025, due to annual equity distribution matters [2]. Group 2: Implementation Status - As of the date of the announcement, the company has not yet implemented the share buyback [3]. Group 3: Price Limit Adjustment Details - The upper limit for the repurchase price has been increased from RMB 24.80 to RMB 35.00 per share, effective from September 9, 2025 [6]. - The adjusted price is set at 150% of the average trading price over the previous 30 trading days [4]. - Based on the total share capital of 168,309,120 shares, the estimated minimum and maximum number of shares to be repurchased are approximately 428,571 shares and 857,142 shares, respectively [4]. Group 4: Impact of Price Adjustment - The adjustment of the repurchase price limit is intended to ensure the successful implementation of the buyback and is not expected to negatively impact the company's operations, finances, research and development, profitability, or future development [7]. Group 5: Decision-Making Process - The adjustment was approved during the ninth meeting of the fourth board of directors and the ninth meeting of the fourth supervisory board held on September 8, 2025, without the need for shareholder approval [8][12].
嘉必优生物技术(武汉)股份有限公司 关于调整第二期以集中竞价方式回购公司股份价格上限的公告